Phase I trial of TR-1, a replacement therapy of wild type p53/p21, in patients with ovarian, breast or colon cancer.

Trial Profile

Phase I trial of TR-1, a replacement therapy of wild type p53/p21, in patients with ovarian, breast or colon cancer.

Planning
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs TR 1 (Primary)
  • Indications Breast cancer; Colon cancer; Ovarian cancer
  • Focus Adverse reactions
  • Sponsors Sellas Life Sciences Group
  • Most Recent Events

    • 29 Mar 2016 According to Sellas Life Sciences media release, the company plans to initiate this study by early 2017.
    • 29 Mar 2016 Planned initiation date changed from 1 Apr 2016 to 1 Jan 2017, according to Sellas Life Sciences media release.
    • 11 Nov 2015 Planned initiation date changed from 1 Dec 2015 to 1 Apr 2016 according to a Sellas Life Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top